These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8452352)

  • 21. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis.
    Conte JE
    J Infect Dis; 1991 Jan; 163(1):169-75. PubMed ID: 1984463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meropenem pharmacokinetics in the newborn.
    van den Anker JN; Pokorna P; Kinzig-Schippers M; Martinkova J; de Groot R; Drusano GL; Sorgel F
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3871-9. PubMed ID: 19581463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.
    Byun SY; Jeong JW; Choi JH; Lee KP; Youn HY; Maeng HJ; Song KH; Koo TS; Seo KW
    J Vet Pharmacol Ther; 2016 Dec; 39(6):560-565. PubMed ID: 27302674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
    Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency.
    Humbert G; Fillastre JP; Leroy A; Godin M; Van Winzum C
    Rev Infect Dis; 1979; 1(1):118-26. PubMed ID: 318213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
    Van der Auwera P; Stolear JC; George B; Dudley MN
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1491-7. PubMed ID: 2221856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
    Kitzes-Cohen R; Farin D; Piva G; De Myttenaere-Bursztein SA
    Int J Antimicrob Agents; 2002 Feb; 19(2):105-10. PubMed ID: 11850162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of vancomycin in patients with various degrees of renal function.
    Matzke GR; McGory RW; Halstenson CE; Keane WF
    Antimicrob Agents Chemother; 1984 Apr; 25(4):433-7. PubMed ID: 6732213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem clinical pharmacokinetics.
    Mouton JW; van den Anker JN
    Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.